Covered recipient · General Payments record
JASON MILLER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$36.85
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $36.85 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Indivior Inc. | $22.11 | 1 |
| Bioventus LLC | $14.74 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JASON MILLER
NPI 1285746974 · CMS profile ID 194371
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1285746974?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285746974?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285746974?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JASON MILLER, NPI 1285746974, CMS profile ID 194371, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1285746974?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $36.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bioventus LLC | $14.74 | 11/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026713913 | CMS |
| Indivior Inc. | $22.11 | 11/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034249397 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2021 | Principal investigator | $17,303.33 | 9 |
| PY2020 | Principal investigator | $117,506.77 | 50 |
| PY2019 | Principal investigator | $733,525.99 | 145 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
145 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan Inc. | $261.14 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670119295 |
| Principal investigator 1 | Allergan Inc. | $2,043.24 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670119675 |
| Principal investigator 1 | Allergan Inc. | $591.50 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670119939 |
| Principal investigator 1 | Allergan Inc. | $100.00 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670122495 |
| Principal investigator 1 | Allergan Inc. | $600.00 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670123503 |
| Principal investigator 1 | Allergan Inc. | $14,038.09 | 12/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670127189 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $2,857.69 | 12/20/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-055 | No dispute reported | 06/30/2026 | 699990483 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $5,517.30 | 12/20/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699990525 |
| Principal investigator 1 | Allergan Inc. | $520.00 | 12/19/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670117366 |
| Principal investigator 1 | Eisai Inc. | $1,702.00 | 12/17/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552551 |
| Principal investigator 1 | Eisai Inc. | $1,470.00 | 12/17/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552553 |
| Principal investigator 1 | Eisai Inc. | $1,733.00 | 12/17/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552555 |
| Principal investigator 1 | Allergan Inc. | $10,627.65 | 12/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670112521 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $40,628.33 | 12/05/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699990443 |
| Principal investigator 1 | Allergan Inc. | $3,220.50 | 11/13/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670096423 |
| Principal investigator 1 | Allergan Inc. | $6,432.45 | 11/13/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670096991 |
| Principal investigator 1 | Allergan Inc. | $1,476.30 | 11/13/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670097353 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $1,374.12 | 11/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879453 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $3,391.32 | 11/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705879461 |
| Principal investigator 1 | Allergan Inc. | $9,081.05 | 11/05/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670094699 |
| Principal investigator 1 | Allergan Inc. | $4,000.00 | 11/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670093495 |
| Principal investigator 1 | Allergan Inc. | $666.24 | 10/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670093241 |
| Principal investigator 1 | Eisai Inc. | $1,370.00 | 10/24/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552531 |
| Principal investigator 1 | Genentech, Inc. | $5,060.00 | 10/24/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681098169 |
| Principal investigator 1 | Allergan Inc. | $225.00 | 10/22/2019 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | No dispute reported | 06/30/2026 | 670088245 |
| Principal investigator 1 | Allergan Inc. | $225.00 | 10/22/2019 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670088695 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $7,444.67 | 10/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705879365 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $1,500.00 | 10/18/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699990187 |
| Principal investigator 1 | Eisai Inc. | $3,036.00 | 10/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552533 |
| Principal investigator 1 | Eisai Inc. | $1,635.00 | 10/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552535 |
| Principal investigator 1 | Eisai Inc. | $4,078.00 | 10/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552537 |
| Principal investigator 1 | Eisai Inc. | $2,904.00 | 10/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552539 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $400.00 | 10/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879305 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $1,797.00 | 10/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879307 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $60.00 | 10/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879309 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $500.00 | 10/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879311 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $30.00 | 10/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879313 |
| Principal investigator 1 | Allergan Inc. | $765.00 | 10/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670082863 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 10/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670083473 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 10/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670083573 |
| Principal investigator 1 | Eisai Inc. | $4,614.00 | 10/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552527 |
| Principal investigator 1 | Eisai Inc. | $1,500.00 | 10/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552529 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $3,877.58 | 10/07/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699990101 |
| Principal investigator 1 | Genentech, Inc. | $1,690.00 | 10/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681095373 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,267.80 | 10/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder | No dispute reported | 06/30/2026 | 686168659 |
| Principal investigator 1 | Allergan Inc. | $1,300.00 | 09/26/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670080403 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 09/24/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670079773 |
| Principal investigator 1 | Allergan Inc. | $12,874.40 | 09/20/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670078767 |
| Principal investigator 1 | Allergan Inc. | $3,681.25 | 09/18/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670076343 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $42,042.92 | 09/13/2019 | Non-covered Recipient Entity NEW HOPE CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 | No dispute reported | 06/30/2026 | 696054945 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 09/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670074965 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $130.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879143 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $118.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879145 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $150.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879147 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $250.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879171 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $160.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879173 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $120.00 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705879175 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $7,123.79 | 09/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705879197 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $321.00 | 09/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914813 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $4.11 | 09/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632155709 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $1,500.00 | 09/04/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699989827 |
| Principal investigator 1 | Genentech, Inc. | $8,462.00 | 08/29/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681075627 |
| Principal investigator 1 | Allergan Inc. | $4,000.00 | 08/23/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670069349 |
| Principal investigator 1 | Allergan Inc. | $8,053.15 | 08/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670067729 |
| Principal investigator 1 | Allergan Inc. | $2,280.00 | 08/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670066753 |
| Principal investigator 1 | Allergan Inc. | $11,405.70 | 08/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670066981 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $1,750.00 | 08/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914817 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $22.43 | 08/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632155719 |
| Principal investigator 1 | Eisai Inc. | $1,844.00 | 08/13/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552541 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $2,030.22 | 08/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914819 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $26.02 | 08/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632155723 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $5,999.76 | 08/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878999 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $8,119.12 | 08/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705879049 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 08/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670063235 |
| Principal investigator 1 | Allergan Inc. | $7,500.00 | 08/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670063239 |
| Principal investigator 1 | Allergan Inc. | $500.00 | 08/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670063243 |
| Principal investigator 1 | Allergan Inc. | $750.00 | 08/01/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670063249 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $3,923.39 | 07/30/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878977 |
| Principal investigator 1 | Allergan Inc. | $5,406.45 | 07/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670057583 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $7,515.47 | 07/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878911 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $5,334.55 | 07/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705878933 |
| Principal investigator 1 | Allergan Inc. | $615.00 | 07/11/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670056303 |
| Principal investigator 1 | Allergan Inc. | $400.00 | 07/11/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670056373 |
| Principal investigator 1 | Allergan Inc. | $615.00 | 07/11/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670056409 |
| Principal investigator 1 | Allergan Inc. | $660.00 | 07/09/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670055909 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $4,490.19 | 07/09/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878865 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $9,750.00 | 07/05/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-055 | No dispute reported | 06/30/2026 | 699989503 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $1,514.00 | 07/05/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699989517 |
| Principal investigator 1 | Allergan Inc. | $712.50 | 07/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670054737 |
| Principal investigator 1 | Allergan Inc. | $14,763.00 | 06/25/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670052939 |
| Principal investigator 1 | Allergan Inc. | $400.00 | 06/25/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670053585 |
| Principal investigator 1 | H. Lundbeck A S | $2,983.10 | 06/11/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD | No dispute reported | 06/30/2026 | 681159910 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $5,566.95 | 06/11/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878721 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $9,750.00 | 06/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | ACP-103-059 | No dispute reported | 06/30/2026 | 699989387 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $429.00 | 06/06/2019 | Non-covered Recipient Entity CLINICAL TRIAL SOURCE LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914815 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $5.49 | 06/06/2019 | Non-covered Recipient Entity CLINICAL TRIAL SOURCE LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632155715 |
| Principal investigator 1 | Eisai Inc. | $1,950.00 | 06/04/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552543 |
| Principal investigator 1 | Eisai Inc. | $1,912.30 | 06/04/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552545 |
| Principal investigator 1 | Allergan Inc. | $1,497.66 | 05/21/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670046835 |
| Principal investigator 1 | Genentech, Inc. | $9,996.00 | 05/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681081127 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $9,887.39 | 05/14/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705878517 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $60.00 | 05/07/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878459 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $60.00 | 05/07/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878485 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $59.00 | 05/07/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878487 |
| Principal investigator 1 | Allergan Inc. | $2,754.05 | 04/23/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670039567 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 04/23/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670040475 |
| Principal investigator 1 | Eisai Inc. | $1,370.00 | 04/23/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552547 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 04/23/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder | No dispute reported | 06/30/2026 | 686168661 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,082.50 | 04/16/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | No dispute reported | 06/30/2026 | 696054170 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $117,273.84 | 04/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696054099 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $9,422.79 | 04/10/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 1, SINGLE-DOSE, SEQUENTIAL COHORT, NONRANDOMIZED CROSSOVER TRIAL TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORAL BREXPIPRAZOLE IN CHILDREN 6 TO 13 YEARS OLD WITH CENTRAL NERVOUS SYSTEM DISORDERS | No dispute reported | 06/30/2026 | 696053971 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 04/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670035487 |
| Principal investigator 1 | Allergan Inc. | $200.00 | 04/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670035631 |
| Principal investigator 1 | Allergan Inc. | $1,499.80 | 04/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670035635 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $2,459.84 | 04/02/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878347 |
| Principal investigator 1 | Allergan Inc. | $11,223.30 | 03/19/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670031451 |
| Principal investigator 1 | Eisai Inc. | $1,950.00 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552519 |
| Principal investigator 1 | Eisai Inc. | $1,912.30 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552521 |
| Principal investigator 1 | Eisai Inc. | $24,206.08 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552525 |
| Principal investigator 1 | Eisai Inc. | $195.00 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552549 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $7,173.45 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877989 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $13,844.69 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705878021 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $3,831.27 | 03/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705878055 |
| Principal investigator 1 | Allergan Inc. | $12,105.00 | 03/07/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670029461 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,833.01 | 03/06/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696053475 |
| Principal investigator 1 | Allergan Inc. | $6,484.70 | 02/28/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670028186 |
| Principal investigator 1 | Genentech, Inc. | $3,849.00 | 02/25/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681094653 |
| Principal investigator 1 | Allergan Inc. | $2,314.20 | 02/19/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670025513 |
| Principal investigator 1 | Allergan Inc. | $8,670.65 | 02/19/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670025715 |
| Principal investigator 1 | Genentech, Inc. | $5,371.00 | 02/18/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | PRODROMAL TO MILD AD | No dispute reported | 06/30/2026 | 681094331 |
| Principal investigator 1 | Allergan Inc. | $955.00 | 02/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670024207 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $2,711.37 | 02/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877709 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $7,249.21 | 02/12/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705877773 |
| Principal investigator 1 | Eli Lilly and Company | $8,035.20 | 02/04/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | No dispute reported | 06/30/2026 | 654289467 |
| Principal investigator 1 | Eli Lilly and Company | $891.55 | 01/31/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | No dispute reported | 06/30/2026 | 654288781 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 01/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670018769 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $9,918.36 | 01/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877463 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $9,053.00 | 01/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877499 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $3,083.90 | 01/22/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 705877521 |
| Principal investigator 1 | Allergan Inc. | $19,994.65 | 01/15/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND | No dispute reported | 06/30/2026 | 670016487 |
| Principal investigator 1 | Allergan Inc. | $1,500.00 | 01/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670015697 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $877.50 | 01/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877407 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $985.50 | 01/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877409 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $60.00 | 01/08/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS | ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT | No dispute reported | 06/30/2026 | 705877411 |
| Principal investigator 1 | Eisai Inc. | $1,899.00 | 01/03/2019 | Non-covered Recipient Entity CLINICAL TRIALS OF TEXAS INC | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | No dispute reported | 06/30/2026 | 702552523 |